20 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
and will compete for market share with them.
The Biologics Price Competition and Innovation Act of 2009, which is included in the 2010 Patient Protection
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
over competitive biosimilar products and will compete for market share with them.
The Biologics Price Competition and Innovation Act of 2009, which
8-K
EX-99.1
ZYME
Zymeworks Inc.
6 Mar 24
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
4:13pm
highlighting the innovation within our pipeline. These IND submissions, along with additional planned submissions over the next two years, provide
8-K
EX-99.1
vfijh7hiafljn66zxtg
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
424B5
k07yie9do13gepz98qo
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
v2xoc81jutvks
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
n99u7t x0i92byfq5
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
DEF 14A
rv1vgfv16kzq0 ss
25 Nov 22
Definitive proxy
6:16am
424B5
q5944j8m3m6o x8
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
odowc0ar
8 Nov 22
Quarterly report
4:09pm
424B5
p18fiwhr0habs5
21 Oct 22
Prospectus supplement for primary offering
4:16pm
424B5
p77ojn
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next